Skip to content
Screener

Indivior Pharmaceuticals, Inc. INDV Business Segments — Net revenue

Similar metrics at other companies

Marvell Technology, Inc. logo
MRVLReportable Segment — Net revenue
$2.42B+27.6%
Marqeta logo
MQReportable Segment — Net revenue
$165.8M+19.2%
ARH
ARHSReportable Segment — Net revenue
$384.9M+7.4%
MaxLinear logo
MXLReportable Segment — Net revenue
$168.85M+55.2%
EA
EAReportable Segment — Net revenue
$2.12B+11.9%
Synaptics logo
SYNAReportable Segment — Net revenue
$294.2M+10.4%

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.57B+66.3%
Enterprise value$4.9B+88.3%
P/E18.2×-7.2×
P/S3.5×+1.2×

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%—

Returns & leverage

See full
Return on equity-117%—
Debt / equity-3.5×—
Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:02 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028850
Line itemThree Months Ended March 31, 20262025
PERSERIS154
Total U.S.272222
Rest of World4544
Net revenue317266
Cost of sales4044
Gross profit277221
Operating expenses:
Selling, general and administrative124133

Item 1. Unaudited Condensed Financial Statements.

FAQ

What is Indivior Pharmaceuticals, Inc.'s business segments — net revenue?
Indivior Pharmaceuticals, Inc. (INDV) reported business segments — net revenue of $317M in Q1 2026.
How has Indivior Pharmaceuticals, Inc.'s business segments — net revenue changed year-over-year?
Indivior Pharmaceuticals, Inc.'s business segments — net revenue increased by 19.2% year-over-year, from $266M to $317M.
What is the long-term trend for Indivior Pharmaceuticals, Inc.'s business segments — net revenue?
Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc.'s business segments — net revenue has grown at a 11.2% compound annual growth rate (CAGR), from $901M to $1.24B.
What does business segments — net revenue mean?
Represents the total gross sales generated by the reportable business segment after deductions for returns, allowances, and discounts. This metric serves as the primary indicator of the segment's market demand and top-line growth performance.

Ask your AI about Indivior Pharmaceuticals, Inc.'s business segments — net revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude